arrow
L

Luca Paruzzo

Perelman School of Medicine at the University of Pennsylvania
H指数:16
被引数:986

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

出版更正:CD19 CAR T细胞在B细胞淋巴瘤中的十年持久性

2026-08-260
OAAI
Decade-long persistence of CD19 CAR T cells in B cell lymphomas

CD19 CAR T细胞在B细胞淋巴瘤中的十年持续性

2026-08-100
OA
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

初始CD4+ T细胞和CART输注时的疾病状态与接受二线CAR T疗法的大B细胞淋巴瘤患者的真实世界临床结局相关

2026-05-150
OAAI
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

针对IGHV4-34 b细胞受体的嵌合抗原受体T细胞特异性消除肿瘤性和自身免疫性b细胞

2026-02-040
PRE
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy

CD4 T细胞介导BCMA car-t细胞治疗后car-t细胞相关的免疫相关不良事件

2026-01-150
PRE
Outcomes of relapse after teclistamab therapy in multiple myeloma

接受特昔利珠单抗治疗后多发性骨髓瘤复发的结局

2025-11-050
OAAI
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

基于定向进化的体内再刺激嵌合抗原受体T细胞配体的发现

2025-08-250
OAAI
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE
Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

根据《世界卫生组织分类》第5版,tisagenlecleucel在大B细胞淋巴瘤中的临床活性

BLOOD
IF23.1
2024-11-050
PRE
EZHI/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

EZHI/2抑制提高了CAR和TCR T细胞为基础疗法对多种液体和实体肿瘤的抗肿瘤疗效

BLOOD
IF23.1
2024-11-050
PRE
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma

苯达莫司汀作为Brexucabtagene自体淋巴细胞治疗套细胞淋巴瘤的淋巴细胞耗竭

2024-07-013
PRE
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
2024-06-030
PRE
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing

制造过程中嵌合抗原受体T细胞浓度,大小,活力和双色表型的简化测量

2024-05-010
PRE
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

苯达莫司汀用于利索卡塔烯前淋巴细胞耗竭的疗效和安全性

2024-04-220
OAAI
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

苯达莫司汀在axicabtagene ciloleucel之前进行淋巴细胞耗竭是安全的,并且与减少的炎症细胞因子有关

2024-01-268
OAAI